24小时热门版块排行榜

返回列表

当前主题已经存档。

cpucqzj

应助: (幼儿园)
在线:
虫号: 577938

[交流] 有关康涅狄格州大学博后申请的事情请教！！50金币奉送！！

各位对康涅狄格大学了解的大侠，请帮忙
这几天老板打算帮我推荐到康涅狄格大学做博后
但我对该校尤其是目标导师知之甚少，毕竟又是老板介绍的，如果贸然答应想不去就不好了，但也不能拖太久，总要给他个答复的。
先不说废话了，把目标老板信息贴上来吧大家帮我拿个主意
Diane J. Burgess
Ph.D.
Board of Trustees Distinguished Professor
Professor of Pharmaceutics
University of Connecticut
School of Pharmacy
虽然据说发过100篇以上文章，但大多在3-5分之间，最高的6.5，也有很多2分以下的，头衔好像挺多，是什么特聘教授什么协会主席什么药典委员会生物制药评审专家等，拿过两次校优秀教师奖。我总觉得她侧重于教学和行政，要不然应该有10分以上的文章出来的。
她的方向和我的很吻合，是做高分子药物载体的，研究界面化学，药物控释等，如果去了，就不用为工作和各种申请烦心，只是去了如果没有很好的平台发点牛的paper，也是不太值得的。本人现在又三篇3.0以上文章，journal of controlled release, nanotechnology, pharmaceutical research. 总觉得我在国内已经有5分的文章了，再到国外辛辛苦苦还是很难发7分以上的文章，总觉得有点不情愿，但是这毕竟是机会，现在出国也是很烦而且也不容易找到太牛的实验室。我很愁，请大家帮忙。
（以下是她的详细情况，请热心大侠略看，谢谢！！）

Diane J. Burgess
Ph.D.
Board of Trustees Distinguished Professor
Professor of Pharmaceutics

University of Connecticut
School of Pharmacy, Room 432
69 North Eagleville Road, Unit 3092
Storrs, Connecticut 06269-3092

Phone: (860) 486-3760
Fax: (860) 486-2076
E-Mail: d.burgess@uconn.edu

Educational Background
◊  Postdoctural Research, Universities of Amsterdam, Nottingham, and North Carolina
◊ Ph.D., University of London, United Kingdom
◊ B.Sc., University of Strathclyde, Glasgow, United Kingdom

Professional Accomplishments

Dr. Burgess was the recipient of the Outstanding Teacher of the Year Award (2005 and 1992).  She was the 2002 President of the American Association of Pharmaceutical Scientists (AAPS) and is an AAPS fellow.  She was recently elected Vice President of the Controlled Release Society and will be the 2009-2010 President.  She is currently a member of the USP Biopharmaceuticals Expert committee and is a member of the USP Advisory Panel on Injectables.  Dr. Burgess was an editor for AAPSharmsci (1999-2005) and is editor of the Journal of Drug Delivery Science and Technology (2003-present) and serves on the editorial boards of: the Journal of Pharmacy and pharmacology (1997-present); the Journal of Microencapsulationi (1997-present); Crital Reviewers in Therapeutic Drug Carrier Systems (2004-present); the International Journal of Pharmaceutics (2004-present); and the Journal of Diabetes Science and Technology (2006-present).  In 2001 she underook a sabbatical leave at the Office of Testing and Research at CDER, FDA.  She consults for pharmaceutical, food, cosmetic and other engineering industries on issues related to dispersed systems, in vitro release testing, IVIVC, interfacial chemistry and particle size analysis.

Professional Interests

Dr. Burgess runs a multidisciplinary laboratory.  Research efforts focus on drug delivery systems, in particular, nonoparticles, microspheres, emulsions, liposomes, hydrogels, and novel coatings for implantable devises as well as interfacial chemistry.  Research interests include small molecule drugs, proteins, peptides and DNA therapeutics.  Together with faculty in Chemistry (Dr. Fotios Papadimitrakopoulos) and Electrical Engineering (Dr. Faquir Jain), Dr. Burgess is developing a miniaturized, implantable biosensor for metabalic monitoring.  The team is developing an implantable coating to control tissue response to implantable devices.  Drs. Burgess and Papidimitrakopoulos are using quantum dots to investigate intracellular traficking of DNA therapeutics and vectors.  Dr. Burgess' group is developing in vitro performance tests for controlled release parenterals products and has collaborations with both the Food and Drug Association (FDA) and the United States Pharmacopeia (USP).  This work includes evaluation of in vitro and in vivo correlation (IVIVC) of controlled release parenterals and development of appropriate in vitro release testing methods.  Other important research areas are investigation of both nanoparticle and emulsion stability using a variety interfacial techniques and particle size analysis.

Selected Recent Publications (out of over 100 publications)
1.  B.S. Zolnik, and D.J. Burgess*.  Evaluation of In vivo - In vitro Release of Dexamethasome from PLGA Microspheres. J. Controlled Release 2008 (127) 137-145.

2.  U. Bhardwaj, R. Sura, F. Papadimitrakopoulos, and D.J. Burgess*.  Controlling Acute Inflammation with fast-releasing dexamethasone PLGA microsphere/PVA hydrogel composites for implantable devices.  Journal of Diabetes Science and Technology 2007, 1(1) 8-17.

3.  S.D. Patil, F. Papidimitrakopoulos, and D.J. Burgess*.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J. Controlled Release 2007, 117(1) 68-79.

4.  C. Srinivasan, J. Lee, F. Papadimitrakopoulos, L.K. Silbart, M.H. Zhao and D.J. Burgess*.  Labeling and intracellular tracking of functionally active plasmid DNA with semiconductor quantum dots.  Molecular Therapy 2006, 14(2) 192-201.

5.  S.D. Patil, D.G. Rhodes, and D.J. Burgess*.  Bio-physical characterization of a novel anionic liposomal delivery system.  Biochimica et Biophysica Acta. 2005; 1711(1):1-11.
  Top ten most downloaded articles of 2005 in BBA.

6.  S.D. Patil, D.G. Rhodes and D.J. Burgess*.  DNA-based therapeutics and their delivery systems: A comprehensive review.  The AAPS J. 2005;7(1):article 9.
  2007 Outstanding Manuscript Award, The AAPS Journal

7.  S.D. Patil, D.G. Rhodes and D.J. Burgess*.  Anionic liposomal delivery system for DNA transfection.  The AAPS J. 2004:6(4);article 29.

8.  J. Jiao and D.J. Burgess*.  Ostwald ripening of water-in-hydrocarbon emulsions.  J. Coll. Interface Sci. 2003;264(2):506-516.

回复此楼